Heart & Lung: The Journal of Acute and Critical Care
Volume 38, Issue 3 , Pages 238-242 , May 2009

Cardiac arrest from acquired long QT syndrome: A case report

  • Teri M. Kozik, MS, RN

      Affiliations

    • Saint Mary's Regional Medical Center, Reno, Nevada
    • College of Nursing, The University of Arizona, Tucson, Arizona
    • Corresponding Author InformationReprint requests: Teri M. Kozik, RN, MS, CCRN, Cardiovascular/Critical Care Clinical Nurse Specialist, Saint Mary's Regional Medical Center, 235 W. 6th Street, Reno NV 89503
    • ,
  • Shu-Fen Wung, PhD, RN, ACNP-BC, FAAN

      Affiliations

    • College of Nursing, The University of Arizona, Tucson, Arizona

References 

  1. Mank-Seymour AR, Richmond JI, Wood LS, Reynolds JM, Fan YT, Warnes GR, et al. Association of torsades de pointes with novel and known single nucleotide polymorphisms in long QT syndrome genes. Am Heart J. 2006;152:1116–1122
  2. LaPointe NM, Curtis LH, Chan KA, Kramer JM, Lafata JE, Gurwitz JH, et al. Frequency of high-risk use of QT-prolonging medications. Pharmacoepidemiol Drug Saf. 2006;15:361–368
  3. Kunkler K. Acquired long QT syndrome: risk assessment, prudent prescribing and monitoring, and patient education. J Am Acad Nurse Pract. 2002;14:382–389
  4. Justo D, Zeltser D. Torsades de pointes induced by antibiotics. Eur J Intern Med. 2006;17:254–259
  5. Aslam AF, Aslam AK, Vasavada NC, Khan IA. Hypothermia: evaluation, electrocardiographic manifestations, and management. Am J Med. 2006;119:297–301
  6. Al-Khatib SM, LaPointe NM, Kramer JM, Califf RM. What clinicians should know about the QT interval. JAMA. 2003;289:2120–2127
  7. Lankipalli RS, Zhu T, Guo D, Yan G-X. Mechanisms underlying arrhythmogenesis in long QT syndrome. J Electrocardiol. 2005;38:69–73
  8. Cubeddu LX. QT prolongation and fatal arrhythmias: a review of clinical implications and effects of drugs. Am J Ther. 2003;106:452–457
  9. Owens RC. QT prolongation with antimicrobial agents. Drugs. 2004;64:1091–1124
  10. Tisdale JE, Kovacs R, Mi D, MoCabe GP, Cariera BL, Sharma N, et al. Accuracy of uncorrected versus corrected QT interval for prediction of torsades de pointes associated with intravenous haloperidol. Pharmacotherapy. 2007;27:175–182
  11. Karjalainen J, Viitasalo M, Manttari M, Manninen V. Relation between QT intervals and heart rates from 40 to 120 beats/min in rest electrocardiograms of men and a simple method to adjust QT interval values. J Am Coll Cardiol. 1994;23:1547–1553
  12. Milne JR, Ward DE, Spurrell RA, Camm AJ. The ventricular paced QT interval—the effects of rate and exercise. Pacing Clin Electrophysiol. 1982;5:352–358
  13. Moss AJ, Zareba W, Benhorin J, Coudere JP, Kennedy H, Locati-Heilbron E, et al. ISHNE guidelines for electrocardiographic evaluation of drug-related QT prolongation and other alterations in ventricular repolarization: task force summary (A report of the Task Force of the International Society for Holter and Noninvasive Electrocardiology (ISHNE), Committee on Ventricular Repolarization). Ann Noninvasive Electrocardiol. 2001;6:333–341
  14. Sommargren CE, Drew BJ. Preventing torsades de pointes by careful cardiac monitoring in hospital settings. AACN Adv Crit Care. 2007;18:285–293
  15. Darpo B, Nebout T, Sager PT. Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human use E14 Guideline. J Clin Pharmacol. 2006;46:498–507
  16. Darpo B, Agin M, Kazierad DJ, Layton G, Muirhead G, Gray P, et al. Man versus machine: is there an optimal method for QT measurements in thorough QT studies?. J Clin Pharmacol. 2006;46:598–612
  17. Kelly HG, Fay JE, Lavery SG. Thioridazine hydrochloride (Mellaril): its effects on the electrocardiogram and a report of two fatalities with electrocardiographic abnormalities. Can Med Assoc J. 1963;89:546–554
  18. Curtis LH, Ostegye T, Sendersky V, Hutchison S, Allen LaPointe NM, Al-Khatib SM, et al. Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. Am J Med. 2003;114:135–141
  19. Sala M, Vicentini A, Brambilla P, Montomoli C, Jogia JR, Caverzasi E, et al. QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy. Ann Gen Psychiatry. 2005;4:1–6
  20. Thomas D, Gut B, Wendt-Nordahl G, Kiehn J. The antidepressant drug fluoxetine is an inhibitor of human ether-a-go-go-related gene (HERG) potassium channels. J Pharmacol Exp Ther. 2002;300:543–548
  21. Tarantino P, Appleton N, Lansdell K. Effect of trazodone on hERG channel current and QT-interval. Eur J Pharmacol. 2005;510:75–85
  22. Winkler D, Ortner R, Pirek E, Aschauer H, Kasper S. Trazodone-induced cardiac arrhythmias: a report of two cases. Hum Psychopharmacol. 2006;21:61–62
  23. Burgess CD, Hames TK, George CF. The electrocardiographic and anticholinergic effects of trazodone and imipramine in man. Eur J Clin Pharmacol. 1982;23:417–421
  24. Rajamani S, Eckhardt LL, Valdivia CR, Klemens CA, Gillman BM, Anderson CL, et al. Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine. Br J Pharmacol. 2006;149:481–489
  25. Pacher P, Kecskemeti V. Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?. Curr Pharm Des. 2004;10:2463–2475
  26. Park KS, Kong ID, Park KC, Lee JW. Fluoxetine inhibits L-type Ca2+ and transient outward K+ currents in rat ventricular myocytes. Yonsei Med J. 1999;40:144–151
  27. Roden DM, Viswanathan PC. Genetics of acquired long QT syndrome. J Clin Invest. 2005;115:2025–2032
  28. Drew BJ, Califf RM, Funk M, Kaufman ES, Krucoff MW, Laks MM, et al. Practice standards for electrocardiographic monitoring in hospital settings (An American Heart Association scientific statement from the Councils on Cardiovascular Nursing, Clinical Cardiology, and Cardiovascular Disease in the Young). Circulation. 2004;110:2721–2746
  29. Drew B, Funk M. Practice standards for ECG monitoring in hospital settings: executive summary and guide for implementation. Crit Care Nurs Clin N Am. 2006;18:157–168
  30. Drew BJ. Pulling it all together. AACN Adv Crit Care. 2007;18:305–317
  31. Viskin S. Long QT syndromes and torsades de pointes. Lancet. 1999;354:1625–1633
  32. Vincent GM. Prevention of drug-induced long QT syndrome: gender, chemistry, and education. J Cardiovasc Electrophysiol. 2001;12:546–547

PII: S0147-9563(08)00157-X

doi: 10.1016/j.hrtlng.2008.08.002

Heart & Lung: The Journal of Acute and Critical Care
Volume 38, Issue 3 , Pages 238-242 , May 2009

Article Tools

* Image Usage & Resolution